­
­
­
­

Inventi Impact: Clinical Research

Articles

  • Inventi:pcr/33487/20
    The Metabolic Effects of Cynara Supplementation in Overweight and Obese Class I Subjects with Newly Detected Impaired Fasting Glycemia: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial
    Research 2021 : January - March
    llMariangela Rondanelli, Antonella Riva, Giovanna Petrangolini, Pietro Allegrini, Luisa Bernardinelli, Teresa Fazia, Gabriella Peroni, Clara Gasparri, Mara Nichetti, Milena Anna Faliva, Maurizio Naso, Simone Perna

    Impaired fasting glucose (IFG) is a condition that precedes diabetes and increases the\nrisk of developing it. Studies support the hypoglycemic effect of Cynara scolymus (Cs) extracts due\nto the content of chlorogenic acid, which is a potent inhibitor of glucose 6-phosphate translocase\nand of dicaffeoylquinic acid derivatives that modulate the activity of alpha-glucosidase. Given this\nbackground, we investigated whether a new highly standardized Cs extract could improve glycemic\ncontrol, insulin sensitivity and other metabolic parameters (total cholesterol (TC), low-density\nlipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C) Triglycerides,\nApolipo protein B (ApoB), Apolipo protein A (ApoA), waist circumference, visceral adipose tissue\n(VAT) by dual-energy X-ray absorptiometry (DXA) in overweight subjects...............................

    How to Cite this Article
    Attribution/ CC Compliant Citation: Rondanelli, Mariangela, et al. \"The Metabolic Effects of Cynara Supplementation in\nOverweight and Obese Class I Subjects with Newly Detected Impaired Fasting Glycemia: A Double-Blind, Placebo-\nControlled, Randomized Clinical Trial.\" Nutrients 12.11 (2020): 3298.\nhttps://doi:10.3390/nu12113298\nhttp://creativecommons.org/licenses/by/4.0/\nSome formatting elements, header, footer, logos, dates and pagination were modified while adapting this article.
    Download Full Text